• LAST PRICE
    8.2000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    3.3300/ 2
  • Ask / Lots
    12.0000/ 10
  • Open / Previous Close
    0.0000 / 8.2000
  • Day Range
    ---
  • 52 Week Range
    Low 5.2200
    High 17.6000
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 8.0545
TimeVolumeONCT
10:15 ET2508.0845
12:00 ET1508.28
12:43 ET1008.2
02:47 ET3378.2
03:16 ET1508.2
03:20 ET6268.2
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesONCT
Oncternal Therapeutics Inc
24.3M
-0.6x
---
United StatesOCX
OncoCyte Corp
24.6M
-0.9x
---
United StatesIGC
IGC Pharma Inc
26.9M
-1.6x
---
United StatesCERO
CERo Therapeutics Holdings Inc
24.3M
-4.7x
---
United StatesBFRG
Bullfrog AI Holdings, Inc.
24.6M
-4.1x
---
United StatesAPTO
Aptose Biosciences Inc
23.7M
-0.2x
---
As of 2024-03-28

Company Information

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.

Contact Information

Headquarters
12230 EL CAMINO REAL, SUITE 230SAN DIEGO, CA, United States 92130
Phone
858-434-1113
Fax
858-408-3010

Executives

Independent Chairman of the Board
David Hale
President, Chief Executive Officer, Director
James Breitmeyer
Chief Financial Officer, Treasurer
Richard Vincent
Chief Technology Officer
Rajesh Krishnan
General Counsel, Secretary
Chase Leavitt

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$24.3M
Revenue (TTM)
$785.0K
Shares Outstanding
3.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.16
EPS
$-13.44
Book Value
$10.19
P/E Ratio
-0.6x
Price/Sales (TTM)
30.9
Price/Cash Flow (TTM)
---
Operating Margin
-5,313.89%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.